-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BKFHQQ08XuwqkTYxnxcCdxRBjAVYFiAG15RxCfD3XBGlf/amX2VwbOBcbYxI8E0i CyHfK40M3K8cNsjp7OCC0w== 0000950157-02-000800.txt : 20021122 0000950157-02-000800.hdr.sgml : 20021122 20021122163833 ACCESSION NUMBER: 0000950157-02-000800 CONFORMED SUBMISSION TYPE: DFAN14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20021122 EFFECTIVENESS DATE: 20021122 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNAPTIC PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000884939 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222859704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DFAN14A SEC ACT: 1934 Act SEC FILE NUMBER: 000-27324 FILM NUMBER: 02838173 BUSINESS ADDRESS: STREET 1: 215 COLLEGE RD CITY: PARAMUS STATE: NJ ZIP: 07652 BUSINESS PHONE: 2012611331 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: H LUNDBECK A S CENTRAL INDEX KEY: 0001206828 IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DFAN14A BUSINESS ADDRESS: STREET 1: 9 OTTILIAVEJ DK 2500 VALBY STREET 2: COPENHAGEN CITY: DENMARK STATE: G7 ZIP: 00000 BUSINESS PHONE: 4526301311 MAIL ADDRESS: STREET 1: 9 OTTILIAVEJ DK 2500 VALBY STREET 2: COPENHAGEN CITY: DENMARK STATE: G7 ZIP: 00000 DFAN14A 1 dfan.txt SCHEDULE 14A SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [ ] Filed by a Party other than the Registrant [X] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [ ] Definitive Additional Materials [X] Soliciting Material Pursuant to Section 240.14a-12 SYNAPTIC PHARMACEUTICAL CORPORATION ----------------------- (Name of Registrant as Specified in its Charter) ----------------------- H. LUNDBECK A/S (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transactions: (5) Total fee paid: - ---------- [ ] Fee paid previously with preliminary materials. [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 2 Set forth as Exhibit 99.1 is the text of a press release issued by H. Lundbeck A/S on November 21, 2002. **THIS FILING IS IDENTICAL TO THE FILING MADE ON NOVEMBER 21, 2O02 (ACCESSION NUMBER 0000950157-02-000793). THIS FILING IS BEING MADE TODAY FOR THE SOLE PURPOSE OF CORRECTLY INDEXING THE FILING TO H. LUNDBECK A/S'S APPROPRIATE EDGAR CENTRAL INDEX KEY (CIK) CODE.** Information Regarding Participants on behalf of Lundbeck - -------------------------------------------------------- Set forth below is the name, business address, principal occupation or employment and citizenship of each director and executive officer of Lundbeck. The name of each person who is a director of Lundbeck is marked with an asterisk. The business address of each person listed below is 9 Ottiliavej, DK-2500 Valby, Copenhagen, Denmark. As of the date of this filing, none of the directors or executive officers listed below individually held any options or shares of Synaptic securities.
- -------------------------------- ------------------------------------------------- ------------------- Name and Business Address Principal Occupation or Employment Citizenship - ------------------------- ---------------------------------- ----------- - -------------------------------- ------------------------------------------------- ------------------- ERIK SPRUNK-JANSEN President and Chief Executive Officer of Denmark Lundbeck - -------------------------------- ------------------------------------------------- ------------------- CLAUS BRAESTRUP Executive Vice President, Research and Denmark Development of Lundbeck - -------------------------------- ------------------------------------------------- ------------------- LARS BANG Senior Vice President, Commercial Operations, Denmark Europe and Overseas of Lundbeck - -------------------------------- ------------------------------------------------- ------------------- HARALD CONRADI-LARSEN Senior Vice President, Human Resource Norway Management of Lundbeck - -------------------------------- ------------------------------------------------- ------------------- Senior Vice President, Corporate Affairs and STIG LOKKE PEDERSEN Commercial Operations, America and Asia of Denmark Lundbeck - -------------------------------- ------------------------------------------------- ------------------- HANS HENRIK MUNCH-JENSEN Senior Vice President, Corporate Finance and Denmark Communication of Lundbeck - -------------------------------- ------------------------------------------------- ------------------- OLE MOESTRUP Senior Vice President, Strategic Marketing of Denmark Lundbeck - -------------------------------- ------------------------------------------------- ------------------- MORTEN KOLD MIKKELSEN Senior Vice President, Supply Operations and Denmark Engineering of Lundbeck - -------------------------------- ------------------------------------------------- ------------------- ARNE V. JENSEN* Chairman Denmark - -------------------------------- ------------------------------------------------- ------------------- OLE STEEN ANDERSEN Executive Vice President, Chief Financial Denmark Officer of Danfoss - -------------------------------- ------------------------------------------------- ------------------- LARS BRUHN* President and Chief Executive Officer of Bruhn Denmark Group - -------------------------------- ------------------------------------------------- ------------------- PETER KURSTEIN* Executive Vice President of Radiometer Medical Denmark - -------------------------------- ------------------------------------------------- ------------------- SVEN DYRLOV MADSEN* Director Denmark - -------------------------------- ------------------------------------------------- ------------------- OLE VAHLGREN* Vice President, U.S. Operations of Lundbeck, Denmark Inc. - -------------------------------- ------------------------------------------------- ------------------- FLEMMING LINDELOV* Chief Executive Officer of Royal Scandinavia Denmark - -------------------------------- ------------------------------------------------- ------------------- JAN GOTTLIEBSEN* Teamleader Liquid & Sterile Production of Denmark Lundbeck - -------------------------------- ------------------------------------------------- ------------------- BIRGIT BUNDGAARD ROSENMEIER* Head of Department, Quality Sterile Production Denmark of Lundbeck - -------------------------------- ------------------------------------------------- ------------------- TORBEN SKARSFELDT* Head of Department, Corporate Licensing of Denmark Lundbeck - -------------------------------- ------------------------------------------------- -------------------
3 INDEX TO EXHIBITS Exhibit No. Exhibit - ----------- ------- 99.1 Press Release issued by H. Lundbeck A/S on November 21, 2002. EX-99.1 3 ex99-1.txt PRESS RELEASE Exhibit 99.1
H. LUNDBECK A/S Ottiliavej 9 Tel +45 36 30 13 11 E-mail investor@lundbeck.com [Lundbeck DK-2500 Valby Kobenhavn Fax +45 36 30 57 42 www.lundbeck.com logo]
Release No 84 21 November 2002 LUNDBECK TO ACQUIRE US-BASED SYNAPTIC H. Lundbeck A/S today announced that it has signed a definitive merger agreement with Synaptic Pharmaceutical Corporation, a US-based drug discovery company, pursuant to which Lundbeck will acquire Synaptic, for $6.50 per common share in cash, or approximately $121 million. The merger is contingent on approval by Synaptics stockholders, regulatory approvals and other customary closing conditions. Synaptic intends to hold a special meeting of its stockholders to approve the merger in the first quarter of 2003 and to close the transaction shortly thereafter. Warburg Pincus Private Equity VIII, L.P., Synaptics largest stockholder, has signed a Voting Agreement with Lundbeck to vote its shares in favour of the transaction. Warburg Pincus owns approximately 35% of Synaptic. The transaction has been approved by the Boards of Directors of Synaptic and Lundbeck. Acquiring Synaptic will enhance Lundbeck's leadership position in CNS research and development and provide a US-base for research and development operations said Erik Sprunk-Jansen, President and CEO of Lundbeck. Synaptic has a number of CNS projects in discovery, pre-clinical and clinical development that are focused in our main therapeutic areas of depression, anxiety and psychosis. In addition, Synaptic provides a foundation for growing our US business. Errol De Souza, President and CEO of Synaptic said, By joining Lundbeck, Synaptic will gain significant scientific, clinical development and financial support to help exploit our proprietary portfolio of G Protein-Coupled Receptors (GPCRs) and bring our discoveries to market faster. Lundbeck has a rich tradition of excellent research & development from which Synaptics projects will benefit. The transaction provides Synaptic stockholders with immediate liquidity and a premium to recent trading prices. In addition, the transaction removes future financing risk for Synaptic in this uncertain environment." The proposed acquisition of Synaptic is a good strategic fit with Lundbecks R&D programme and is expected to lead to a significant increase in clinical development candidates. Synaptics target-driven approach to drug discovery and development is supported by an outstanding scientific team and proprietary technology, said Dr Claus Braestrup, Executive Vice President, Head of R&D at Lundbeck. The objective is to reach a fruitful interaction of the R&D teams in the companies and simultaneously retain Synaptic as an excellent drug discovery and innovation unit. Lundbeck will host a conference call on 21 November 2002 at 4:00 PM (CET, Copenhagen time) concerning the proposed acquisition of Synaptic. To participate in the conference call, please call one of the following call in numbers and quote the password: H. Lundbeck A/S Page 1 of 3 21 November 2002 Lundbeck to acquire US-based Synaptic Release No 84
H. LUNDBECK A/S Ottiliavej 9 Tel +45 36 30 13 11 E-mail investor@lundbeck.com [Lundbeck DK-2500 Valby Kobenhavn Fax +45 36 30 57 42 www.lundbeck.com logo]
UK: +44 (0) 20 8781 0576 US: +1 303 713 7888 Password: Lundbeck A replay will be available one hour after the teleconference and will be accessible for 48 hours. Please call one of the following call in numbers and quote the access code: UK: +44 (0) 20 8288 4459 US: +1 703 736 7336 Access code: 922042 The live call and replay will also be available at: WWW.LUNDBECK.COM/INVESTOR/REPORTSANDPRESENTATIONS/TELECONFERENCE/DEFAULT.ASP The content of this release will have no influence on the H. Lundbeck Group's result for 2002. For 2002 Lundbeck expects an increase in revenue of 20-25% compared to 2001, while the operating profit is expected to increase by 25-30% compared to 2001. Based on management expectations for 2002, Lundbeck also for 2003 expects to reach the company's long-term financial goals, which are an increase in revenue of 10-12% and an increase in operating profit of 12-15%. For further information please contact Hans Henrik Munch-Jensen, CFO of H. Lundbeck A/S, tel +45 36 30 15 11, ext. 2660 or Steen Juul Jensen, Director of Corporate Communication & Investor Relations of H. Lundbeck A/S, tel +45 36 30 13 11, ext. 3006. - ------------------------------------------------------------------------------ Synaptic Pharmaceutical Corporation is a pioneer in the development of pharmaceuticals that target G protein-coupled receptors (GPCRs) to achieve superior efficacy and safety in the treatment of disorders such as depression, diabetes, obesity, pain and incontinence. As of November 21, 2002, Synaptic is collaborating with Grunenthal GmbH on discovering compounds for the alleviation of pain and with Kissei Pharmaceutical Co., Ltd. to identify novel G protein-coupled receptors that can provide new drug discovery targets for Kissei. Glaxo Group Limited, Eli Lilly and Company, Novartis Pharma A.G. and Ranbaxy Laboratories Limited have also been granted licenses by Synaptic. H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2001, the Companys revenue was DKK 7.7 billion. The number of employees is approx. 4,800. ADVISORS Lundbeck was advised by JPMorgan. Synaptic was advised by Bank of America Securities. FORWARD LOOKING STATEMENTS The forward-looking statements contained in this announcement are based on the management's current expectations concerning certain future events and results. These are, of course, subject to uncertainty, and actual results may therefore differ materially from those expressed by the statements. Further, H. Lundbeck A/S Page 2 of 3 21 November 2002 Lundbeck to acquire US-based Synaptic Release No 84
H. LUNDBECK A/S Ottiliavej 9 Tel +45 36 30 13 11 E-mail investor@lundbeck.com [Lundbeck DK-2500 Valby Kobenhavn Fax +45 36 30 57 42 www.lundbeck.com logo]
some of the expectations are based upon assumptions about future events, which may turn out to be incorrect. ADDITIONAL INFORMATION Stockholders of Synaptic are urged to read the proxy statement that Synaptic will file on Schedule 14A with the Securities and Exchange Commission ("SEC") when it becomes available, and any other relevant documents filed or to be filed in the future with the SEC because those documents contain important information about Synaptic, the proposed transactions and related matters. Investors and security holders can obtain free copies of the proxy statement at Synaptic's web site, WWW.SYNAPTICCORP.COM or by contacting Investor Relations, Synaptic Pharmaceutical Corporation, 215 College Road, Paramus, NJ 07652 (Telephone: (201) 261-1331, ext. 1410). Investors and security holders can also obtain free copies of the proxy statement and other documents filed by Synaptic and henceforth by Lundbeck with the SEC in connection with the proposed transactions at the SEC's web site at WWW.SEC.GOV. In addition to the proxy statement, Synaptic files annual, quarterly and special reports, proxy statements and other information with the SEC, each of which are available at the SEC's web site at WWW.SEC.GOV. Lundbeck has not previously filed any reports or other information with the SEC because Lundbeck has no securities registered pursuant to the Securities Exchange Act of 1934, as amended. You may also read and copy any reports, statements and other information filed by Synaptic and henceforth by Lundbeck at the SEC public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information. Synaptic, Lundbeck, and their respective directors, executive officers and certain members of management and other employees may be deemed to be participants in the solicitation of proxies of Synaptic's stockholders to approve the proposed transactions. Such individuals may have interests in the transactions, including as a result of holding options or shares of Synaptic's stock. Information regarding Lundbeck and its directors and officers is contained in its DFAN 14A, filed with the SEC on November 21, 2002. Information regarding Synaptic and its directors and officers is contained in its proxy statement on Schedule 14A, filed with the SEC on April 8, 2002. H. Lundbeck A/S Page 3 of 3 21 November 2002 Lundbeck to acquire US-based Synaptic Release No 84 -----END PRIVACY-ENHANCED MESSAGE-----